InvestorsObserver
×
News Home

Is Neurobo Pharmaceuticals Inc (NRBO) Stock a Bad Value Tuesday?

Tuesday, February 23, 2021 01:44 PM | InvestorsObserver Analysts

Mentioned in this article

Is Neurobo Pharmaceuticals Inc (NRBO) Stock a Bad Value Tuesday?

A rating of 28 puts Neurobo Pharmaceuticals Inc (NRBO) near the top of the Healthcare sector according to InvestorsObserver.

Neurobo Pharmaceuticals Inc's score of 28 means that it ranks higher than 28% of stocks in the sector. In addition, its overall score of 3 ranks it higher than 3% of all stocks.

Overall Score - 3
NRBO has an Overall Score of 3. Find out what this means to you and get the rest of the rankings on NRBO!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies in the healthcare sector can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the best stocks in that sector.

Not only are these scores easy to understand, but it is easy to compare stocks to each other. You can find the best stock in healthcare or look for the sector that has the highest average score.

The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Neurobo Pharmaceuticals Inc Stock Today?

Neurobo Pharmaceuticals Inc (NRBO) stock is trading at $4.66 as of 1:39 PM on Tuesday, Feb 23, a loss of -$0.59, or -11.24% from the previous closing price of $5.25. The stock has traded between $4.45 and $5.13 so far today. Volume today is low. So far 423,715 shares have traded compared to average volume of 635,524 shares.

Click Here to get the full Stock Score Report on Neurobo Pharmaceuticals Inc (NRBO) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App